Bank of China Securities released a research report on April 22 stating that it gave Bairen Healthcare (688198.SH) a purchase rating. The main reasons for the rating include: 1) the approval of the first domestic vascular biological supplement, which is expected to fill the gap in the industry; 2) the broad market space is expected to help the company achieve accelerated growth in performance. (Mainichi Keizai Shimbun)
中银证券4月22日发布研报称，给予佰仁医疗（688198.SH）买入评级。评级理由主要包括：1）国内首款血管生物补片获批，有望填补行业空白；2）市场空间广阔，有望帮助公司实现业绩加速增长。（每日经济新闻）
Bank of China Securities released a research report on April 22 stating that it gave Bairen Healthcare (688198.SH) a purchase rating. The main reasons for the rating include: 1) the approval of the first domestic vascular biological supplement, which is e
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.